Authors:
Goshorn, S
Sanderson, J
Axworthy, D
Lin, YK
Hylarides, M
Schultz, J
Citation: S. Goshorn et al., Preclinical evaluation of a humanized NR-LU-10 antibody-streptavidin fusion protein for pretargeted cancer therapy, CANC BIO R, 16(2), 2001, pp. 109-123
Authors:
Press, OW
Corcoran, M
Subbiah, K
Hamlin, DK
Wilbur, DS
Johnson, T
Theodore, L
Yau, E
Mallett, R
Meyer, DL
Axworthy, D
Citation: Ow. Press et al., A comparative evaluation of conventional and pretargeted radioimmunotherapy of CD20-expressing lymphoma xenografts, BLOOD, 98(8), 2001, pp. 2535-2543
Authors:
Weiden, PL
Breitz, HB
Press, O
Appelbaum, JW
Bryan, JK
Gaffigan, S
Stone, D
Axworthy, D
Fisher, D
Reno, J
Citation: Pl. Weiden et al., Pretargeted radioimmunotherapy (PRIT (TM)) for treatment of non-Hodgkin's lymphoma (NHL): Initial phase I/II study results, CANC BIO R, 15(1), 2000, pp. 15-29
Authors:
Knox, SJ
Goris, ML
Tempero, M
Weiden, PL
Gentner, L
Breitz, H
Adams, GP
Axworthy, D
Gaffigan, S
Bryan, K
Fisher, DR
Colcher, D
Horak, ID
Weiner, LM
Citation: Sj. Knox et al., Phase II trial of yttrium-90-DOTA-biotin pretargeted by NR-LU-10 antibody/streptavidin in patients with metastatic colon cancer, CLIN CANC R, 6(2), 2000, pp. 406-414
Authors:
Schultz, J
Lin, YK
Sanderson, J
Zuo, YT
Stone, D
Mallett, R
Wilbert, S
Axworthy, D
Citation: J. Schultz et al., A tetravalent single-chain antibody-streptavidin fusion protein for pretargeted lymphoma therapy, CANCER RES, 60(23), 2000, pp. 6663-6669